Organogenesis Q1 rev $107.6M (+11% YoY); raises FY2023 revenue to $454-466M

Organogenesis Holdings Inc.

2023-Q1 EPS reported -$0.02 revenue$107,642,000

Net revenue $107.6M, up 11% YoY; net loss $3.0M vs $0.9M loss year-ago.
Advanced Wound Care revenue $100.9M (+12% YoY); Surgical & Sports Medicine $6.7M (-4% YoY).
Adjusted EBITDA $3.8M vs $5.0M prior year; adjusted net loss $0.7M.
FY2023 guidance raised: revenue $454-466M, net income $3-11M, adjusted EBITDA $38-49M.
Cash $88.7M, debt $69.9M at March 31, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Organogenesis Holdings Inc. reported first quarter ended March 31, 2023 results: revenue $107.6 million, net income Net loss of $3.0 million, EPS $(0.02) per share. Guidance raised.

Period: first quarter ended March 31, 2023
Revenue: $107.6 million
Net income: Net loss of $3.0 million
EPS: $(0.02) per share
Guidance: raised
Result: reported results

Exact text from the filing

Surgical & Sports Medicine markets, today reported financial results for the first quarter ended March 31, 2023. First Quarter 2023 Financial Results Summary: • Net revenue of $107.6 million for the first quarter of 2023, an increase of $10.5 million compared to net revenue of $97.1 million for the first quarter of 2022. Net revenue for the first quarter of 2023

View on SEC.gov

Browse all earnings releases →

Organogenesis Holdings Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-020572

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.